澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

CLINUVEL PHARMACEUTICALS LTD

10.600

+0.2802.71%

成交量：7.45萬

成交額：77.88萬

市值：5.32億

市盈率：16.47

高：10.610

開：10.320

低：10.260

收：10.320

52周最高：13.933

52周最低：8.350

股本：5,020.07萬

流通股本：4,131.90萬

量比：0.47

換手率：0.18%

股息：0.05

股息率：0.47%

每股收益(TTM):0.644

每股收益(LYR):0.718

淨資產收益率：13.96%

總資產收益率：10.62%

市淨率：2.14

市盈率(LYR):14.76

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股+2.85%

資金流向

資金流入：

資金流出：

新聞資訊

Clinuvel Pharmaceuticals 宣佈戰略重組，重心轉向美國市場

CLINUVEL PHARMACEUTICALS LTD 宣佈將公司總部遷至美國，自2027年1月1日起生效

Clinuvel Pharmaceuticals 將運營資源聚焦於美國藥品研發管線與戰略

加拿大衞生部批准Scenesse用於預防紅細胞生成性原卟啉症光毒性

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/CUV.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"CUV.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","market":"AU","secType":"STK","nameCN":"CLINUVEL PHARMACEUTICALS LTD","latestPrice":10.6,"timestamp":1787638320000,"preClose":10.32,"halted":0,"volume":74465,"delay":0,"changeRate":0.02713178294573637,"nameEN":"CLINUVEL PHARMACEUTICALS LTD","floatShares":41318955,"shares":50200740,"eps":0.643659,"marketStatus":"未開盤","change":0.28,"latestTime":"08-25 16:12:00 AEST","open":10.32,"high":10.61,"low":10.26,"amount":778757,"amplitude":0.033915,"askPrice":10.63,"askSize":114,"bidPrice":10.6,"bidSize":186,"shortable":3,"etf":0,"ttmEps":0.643659,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":10.32,"dividendRate":0.004717,"openAndCloseTimeList":[[1787616000000,1787637600000]],"volumeRatio":0.470836,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CUV.AU","preClose":10.32,"auctionPrice":10.6,"auctionVolume":4812,"auction":3,"marketStatus":"盘后竞价","timestamp":1787638203502}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CUV.AU\",,,,,undefined,":{"symbol":"CUV.AU","floatShares":41318955,"roa":"10.62%","roe":"13.96%","lyrEps":0.717999,"volumeRatio":0.470836,"shares":50200740,"dividePrice":0.05,"high":10.61,"amplitude":0.033915,"preClose":10.32,"low":10.26,"week52Low":8.35,"pbRate":"2.14","psRate":"5.53","week52High":13.933,"institutionHeld":0,"latestPrice":10.6,"committee":0.24,"eps":0.643659,"divideRate":0.004717,"volume":74465,"delay":0,"ttmEps":0.643659,"open":10.32,"prevYearClose":12.46,"prevWeekClose":10.42,"prevMonthClose":9.06,"prevQuarterClose":10.28,"fiveDayClose":10.36,"twentyDayClose":9.81,"sixtyDayClose":9.26,"earningDate":1787760000000,"dividendPayoutRate":0.06921842705277628,"dividendFrequency":"A","dividendGrowthYears":5,"dividendGrowthRate":0,"fiveYearAvgDividendRate":0.0025824359172833843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CUV.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1772060400000,"name":null,"time":"","dateTimestamp":1772024400000,"actualEps":null},{"date":"2025-09-04","symbol":"CUV.AU","amount":0.05,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-09-05","defaultRemindTime":1756944000000,"name":"CLINUVEL PHARMACEUTICALS LTD","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-05","currency":"AUD","dateTimestamp":1756908000000,"payDate":"2025-09-19"},{"date":"2025-08-28","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756339200000,"name":null,"time":"","dateTimestamp":1756303200000,"actualEps":null},{"date":"2025-02-26","symbol":"CUV.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CUV.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2020-09-03","recordDate":"2020-09-04","paymentDate":"2020-09-18","value":0.025,"currency":"AUD"},{"executeDate":"2021-09-02","recordDate":"2021-09-03","paymentDate":"2021-09-17","value":0.025,"currency":"AUD"},{"executeDate":"2022-09-06","recordDate":"2022-09-07","paymentDate":"2022-09-21","value":0.04,"currency":"AUD"},{"executeDate":"2023-09-05","recordDate":"2023-09-06","paymentDate":"2023-09-20","value":0.05,"currency":"AUD"},{"executeDate":"2024-09-05","recordDate":"2024-09-06","paymentDate":"2024-09-20","value":0.05,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CUV.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1174389314","title":"Clinuvel Pharmaceuticals 宣佈戰略重組，重心轉向美國市場","url":"https://stock-news.laohu8.com/highlight/detail?id=1174389314","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174389314?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 09:48","pubTimestamp":1784771302,"startTime":"0","endTime":"0","summary":"CLINUVEL PHARMACEUTICALS LTD宣布了一项重大战略重组计划，旨在将业务重心重新聚焦于美国市场。作为该计划的关键举措，公司企业总部将于2027年1月1日正式迁至美国。\n此次重组将涉及全球范围内的运营调整。公司计划削减10%至20%的全球员工，并将相关职能转移至美国本土。此举旨在集中运营资源，全力支持其在美国的药品研发管线与核心战略的推进。\n通过这次战略转移与重组，Clinuvel Pharmaceuticals 期望能够更深入地接入美国庞大的资本池，为公司未来的研发与扩张提供更强劲的资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CUV.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129418105","title":"CLINUVEL PHARMACEUTICALS LTD 宣佈將公司總部遷至美國，自2027年1月1日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1129418105","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129418105?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 07:12","pubTimestamp":1784761934,"startTime":"0","endTime":"0","summary":"CLINUVEL PHARMACEUTICALS LTD 已正式宣布，其公司总部将迁往美国。这一重大战略举措预计将于2027年1月1日正式生效。此举标志着公司全球运营布局进入新阶段，旨在更贴近关键市场，优化资源配置，并把握未来增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","CUV.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138092619","title":"Clinuvel Pharmaceuticals 將運營資源聚焦於美國藥品研發管線與戰略","url":"https://stock-news.laohu8.com/highlight/detail?id=1138092619","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138092619?lang=zh_tw&edition=fundamental","pubTime":"2026-07-23 07:12","pubTimestamp":1784761930,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals 宣布，将集中其运营资源，以专注于推进其在美国市场的药品研发管线与整体战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157716656","title":"加拿大衞生部批准Scenesse用於預防紅細胞生成性原卟啉症光毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1157716656","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157716656?lang=zh_tw&edition=fundamental","pubTime":"2026-07-13 06:35","pubTimestamp":1783895717,"startTime":"0","endTime":"0","summary":"Clinuvel Pharmaceuticals宣布，其药物Scenesse已获得加拿大卫生部批准，用于预防红细胞生成性原卟啉症患者的光毒性反应。这一监管批准为加拿大受此罕见光敏性疾病困扰的患者带来了新的治疗选择。Scenesse是一种植入皮下的缓释型α-黑素细胞刺激素类似物，旨在通过增加皮肤中的真黑色素生成来增强对紫外线和可见光的天然保护。对于EPP患者而言，暴露于阳光下可能导致剧烈疼痛、灼烧感和皮肤损伤，严重影响生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CUV.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CUV.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","id":"package_au_concept_yyswg","bkCode":"BK7508","changeRate":0.0285}]}}